196 related articles for article (PubMed ID: 26719579)
21. Macrophage migration inhibitory factor expression in ovarian cancer.
Agarwal R; Whang DH; Alvero AB; Visintin I; Lai Y; Segal EA; Schwartz P; Ward D; Rutherford T; Mor G
Am J Obstet Gynecol; 2007 Apr; 196(4):348.e1-5. PubMed ID: 17403417
[TBL] [Abstract][Full Text] [Related]
22. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung.
Koh HM; Kim DC; Kim YM; Song DH
Thorac Cancer; 2019 Dec; 10(12):2209-2217. PubMed ID: 31602798
[TBL] [Abstract][Full Text] [Related]
24. MIF in autoimmunity and novel therapeutic approaches.
Stosic-Grujicic S; Stojanovic I; Nicoletti F
Autoimmun Rev; 2009 Jan; 8(3):244-9. PubMed ID: 18721909
[TBL] [Abstract][Full Text] [Related]
25. Expression of MIF and CD74 in leukemic cell lines: correlation to DR expression destiny.
Georgouli M; Papadimitriou L; Glymenaki M; Patsaki V; Athanassakis I
Biol Chem; 2016 Jun; 397(6):519-28. PubMed ID: 26866879
[TBL] [Abstract][Full Text] [Related]
26. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation.
Dumitru CA; Gholaman H; Trellakis S; Bruderek K; Dominas N; Gu X; Bankfalvi A; Whiteside TL; Lang S; Brandau S
Int J Cancer; 2011 Aug; 129(4):859-69. PubMed ID: 21328346
[TBL] [Abstract][Full Text] [Related]
27. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.
Lopez M; Ghidouche A; Rochas C; Godelaine D; Carrasco J; Colau D; Hames G; Montero-Julian FA; Coulie PG; Olive D
Cancer Immunol Immunother; 2016 Oct; 65(10):1177-88. PubMed ID: 27514672
[TBL] [Abstract][Full Text] [Related]
28. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
29. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
30. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
32. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
Oved K; Lev A; Noy R; Segal D; Reiter Y
Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
[TBL] [Abstract][Full Text] [Related]
33. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer.
Schinagl A; Thiele M; Douillard P; Völkel D; Kenner L; Kazemi Z; Freissmuth M; Scheiflinger F; Kerschbaumer RJ
Oncotarget; 2016 Nov; 7(45):73486-73496. PubMed ID: 27636991
[TBL] [Abstract][Full Text] [Related]
34. Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.
Subbannayya T; Leal-Rojas P; Barbhuiya MA; Raja R; Renuse S; Sathe G; Pinto SM; Syed N; Nanjappa V; Patil AH; Garcia P; Sahasrabuddhe NA; Nair B; Guerrero-Preston R; Navani S; Tiwari PK; Santosh V; Sidransky D; Prasad TS; Gowda H; Roa JC; Pandey A; Chatterjee A
BMC Cancer; 2015 Nov; 15():843. PubMed ID: 26530123
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
36. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
Lev A; Novak H; Segal D; Reiter Y
J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
[TBL] [Abstract][Full Text] [Related]
37. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
Varinelli L; Caccia D; Volpi CC; Caccia C; De Bortoli M; Taverna E; Gualeni AV; Leoni V; Gloghini A; Manenti G; Bongarzone I
Endocr Relat Cancer; 2015 Oct; 22(5):759-75. PubMed ID: 26206776
[TBL] [Abstract][Full Text] [Related]
38. Transient transfection of macrophage migration inhibitory factor small interfering RNA disrupts the biological behavior of oral squamous carcinoma cells.
Zeng J; Quan J; Xia X
Mol Med Rep; 2016 Jan; 13(1):174-80. PubMed ID: 26549761
[TBL] [Abstract][Full Text] [Related]
39. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
40. Recombinant
Jeong H; Lee SY; Seo H; Kim BJ
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
